These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29054584)

  • 21. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
    Klempner SJ; Choueiri TK; Yee E; Doyle LA; Schuppan D; Atkins MB
    J Clin Oncol; 2012 Sep; 30(27):e264-8. PubMed ID: 22802316
    [No Abstract]   [Full Text] [Related]  

  • 22. A case of repigmentation and curling of hair on acitretin therapy.
    Ward PD; Miller HL; Shipman AR
    Clin Exp Dermatol; 2014 Jan; 39(1):91-2. PubMed ID: 24266744
    [No Abstract]   [Full Text] [Related]  

  • 23. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case of severe ulceration induced by pazopanib.
    Goto H; Niwakawa M; Yoshikawa S; Otsuka M; Omodaka T; Yoshimi K; Kiyohara Y
    J Dermatol; 2017 Apr; 44(4):474-476. PubMed ID: 27238880
    [No Abstract]   [Full Text] [Related]  

  • 25. Pazopanib in renal cell carcinoma.
    Sternberg CN
    Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
    [No Abstract]   [Full Text] [Related]  

  • 26. The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.
    Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb S; Shamash J; Stockdale A; Lim L; Nathan P; Chowdury S
    Eur J Cancer; 2013 Mar; 49(4):986-7. PubMed ID: 23138000
    [No Abstract]   [Full Text] [Related]  

  • 27. Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites.
    Tinning AR; Bengtsen C; Jensen NV; Bastholt L; Jensen BL; Madsen K
    Hypertension; 2018 Mar; 71(3):473-480. PubMed ID: 29311252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Metastasized renal cell carcinoma - research subjects needed!].
    Aktuelle Urol; 2014 Mar; 45(2):99. PubMed ID: 24700063
    [No Abstract]   [Full Text] [Related]  

  • 29. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
    Sideras K; Menefee ME; Burton JK; Erlichman C; Bible KC; Ivy SP
    J Clin Oncol; 2010 Jul; 28(19):e312-3. PubMed ID: 20516434
    [No Abstract]   [Full Text] [Related]  

  • 30. Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
    Hioki T; Takama H; Makita S; Chen KR; Watanabe D; Akiyama M
    Eur J Dermatol; 2017 Oct; 27(5):546-547. PubMed ID: 29084643
    [No Abstract]   [Full Text] [Related]  

  • 31. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH; Park I; Lee JL
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Discoloration of hair under the effect of hyroxychloroquine].
    Lecocq P; Wyderkiewicz E; Mikolajczak P; Guerbeau G
    Presse Med; 1999 Apr; 28(14):741. PubMed ID: 10230411
    [No Abstract]   [Full Text] [Related]  

  • 33. [The green hair problem--also in German Democratic Republic].
    Schmidt CW
    Z Arztl Fortbild (Jena); 1983; 77(17):741. PubMed ID: 6649688
    [No Abstract]   [Full Text] [Related]  

  • 34. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
    Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
    Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
    Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
    Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
    Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
    J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib.
    Casado-Verrier B; Pérez-Santos S; Delgado-Mucientes C; Beato-Merino M
    Br J Dermatol; 2014 Dec; 171(6):1559-61. PubMed ID: 24909204
    [No Abstract]   [Full Text] [Related]  

  • 40. Tyrosine Kinase Inhibitors' Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer.
    Elshimy G; Gandhi A; Guo R; Correa R
    J Investig Med High Impact Case Rep; 2020; 8():2324709620936808. PubMed ID: 32583692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.